您的购物车当前为空
ZL006 是一种 nNOS/PSD-95 相互作用抑制剂,能够抑制 NMDA 受体介导的 NO 合成。


为众多的药物研发团队赋能,
让新药发现更简单!
ZL006 是一种 nNOS/PSD-95 相互作用抑制剂,能够抑制 NMDA 受体介导的 NO 合成。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 148 | 现货 | |
| 5 mg | ¥ 337 | 现货 | |
| 10 mg | ¥ 488 | 现货 | |
| 25 mg | ¥ 990 | 现货 | |
| 50 mg | ¥ 1,590 | 现货 | |
| 100 mg | ¥ 2,790 | 现货 | |
| 200 mg | ¥ 3,890 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 383 | 现货 |
ZL006 相关产品
| 产品描述 | ZL006 is an effective inhibitor of nNOS/PSD-95 interaction. ZL006 also inhibits NMDA receptor-mediated NO synthesis. |
| 体外活性 | ZL006 growth inhibition of BCECs is not found at a low concentration of 0.001, 0.01, 0.1, 1, and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is obviously enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs [1][2]. |
| 体内活性 | T7-P-LPs/ZL006 displays a significant enhance in drug accumulation in the brain tissue due to its better brain targeting delivery compared with P-LPs/ZL006 and free ZL006. P-LPs/ZL006 and T7-P-LPs/ZL006 show a significant decrease in drug accumulation in the liver and kidney compared with free ZL006 [1]. |
| 分子量 | 328.15 |
| 分子式 | C14H11Cl2NO4 |
| CAS No. | 1181226-02-7 |
| Smiles | OC(=O)c1ccc(NCc2cc(Cl)cc(Cl)c2O)cc1O |
| 密度 | 1.617 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 29 mg/mL (88.37 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.09 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容